Technical Data
Topoisomerase II (DNA) alpha
The expression of topoisomerase II alpha is strongly restricted to proliferating cells. The topoisomerase II alpha antigen is preferentially expressed during G1, S, G2 and M phase of the cell cycle, while resting, non-cycling cells (G0 phase) lack topoisomerase II alpha. In addition, constantly proliferating cells (e.g. cell lines) react positively to topoisomerase II alpha during the entire cell-cycle. This specificity for proliferating cells might make it a useful tool for determination of the proliferative fraction in solid tumors such as mammary carcinomas and gangliomas.

Suitable for use in Immunohistochemistry, Western Blot, Immunoprecipitation, Immunocytochemistry and Flow Cytometry. Other applications not tested.

Recommended Dilutions:
Western Blot: 1-10ug/ml
Immunohistochemistry: 5-10ug/ml. Strong nuclear staining only in proliferating cells. The epitope recognized by the antibody is also detectable in paraffin-embedded tissue sections.
Immunocytochemistry: 5-10ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

100ug-20CBlue IceHumanMouse
Nuclear protein preparation from the human cell line U937.50
Supplied as a liquid in PBS, pH 7.6, 0.09% sodium azide.
Recognizes a major protein of 170kD which was identified as the human alpha isoform of topoisomerase II. Recognizes a C- terminal alpha-isoenzyme specific epitope missing in topoisomerase II beta.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1 Boege, F. et al. (1995) Am. J. Pathol., June (accepted). 2 Kreipe, H. et al. (1993) Am. J. Pathol. 142, 651. 3 Kreipe, H. et al. (1993) Am. J. Pathol. 142, 3. 4 Tsutsui, K. et al. (1993) J. Biol. Chem. 268, 19076 5 Sampson, S.A. et al. (1992) J. of Pathology 168, 179. 6 Camplejohn, R.S. et al. (1993) Br. J. Cancer 67, 657. 7 Kreipe, H. et al (1993) Cancer Research 53, 1956. 8 Rasbridge et al (1994) Br. J. Cancer 70, 335 9 Wolf, H. K. et al (1994) ACTA Neuropathologica 88, 166.